Appendix 2: Detailed characteristics of 19 studies included in our systematic review and meta-analysis of anticoagulation intensity and risk of hemorrhagic and thromboembolic events (part 1 of 2)

Study	Design	Setting	Drug	Method	Start of OAC use	Indication	N	Age, mean (SD or range)	Female (%)	Mean follow-up (yr)	No. of events		Person-years of observation
											Hemorrhagic events	Thrombo-embolic events	
Rosove et al.[1]	RC	C	W	NR	Before study	VTE, APlA	55	45.5 (17.3)	69	3.0	NR	9	162
Hutten et al.[2]	RC	C	NR	LI	Start of study	VTE	1 303	62.5 (15)	48	0.2	11	34	273
Yasaka et al.[3]	RC	C	W	E	Start of study	AF*	203	68.0 (7.1)	25	1.8	9	18	339
EAFT[4]	RCT	C	NR	E	Start of study	AF*	214	71.0 (NR)	45	2.1	11	21	377
Chimowitz et al.[5]	RCT	C	W	LI	Start of study	CVD	289	64.3 (11.5)	37	1.8	24	40	407
Andersen et al.[6]	RC	C	W	LI	Start of study	VHD	204	62.5 (NR)	42	2.1	14	5	431
Torn et al.[7]	RC	ACC	NR	LI	59% of pts new users	CVD	356	69.0 (24–93)	45	1.8	22	19	614
Cheung et al.[8]	RC	C	W	LI	>1 week before study	AF	555	69.7 (NR)	58	1.6†	18	35	856
ESPRIT[9]	RCT	C	W, PH, A	LI	5% of pts new users	CVD	536	62.0 (10)	28	4.6	31	25	1 408
Poli et al.[10]	PC	ACC	W	LI	31% of pts new users	AF, VTE, IHD, other	903	63.5 (14.1)	41	1.9	84	63	1 408
Tangelder et al.[11]	RCT	C	PH, A	LI	Start of study	PVD	1 326	69.0 (33–93)	45	1.3	80	76	1 699
Kearon et al.[12]	RCT	C	W	LI	Start of study	VTE	738	57.0 (16)	45	2.4	15	11	1 725
Casais et al.[13]	RC	ACC	A	LI	>1 month before study	VTE, VHD, CHF	811	58.5 (5–88)	46	2.5	25	NR	1 959
Palareti et al.[14]	PC	ACC	W, A	LI	<1 month before study	VHD, IHD, CHF, other	2 745	62.4 (8–93)	43	0.7	NR	63	1 980
Palareti et al.[15]	PC	ACC	W, A	LI	<1 month before study	VHD, IHD, CHF, other	2 745	62.4 (8–93)	43	0.7	23	NR	1 980
Van Walraven et al.[16]	RC	C	W	LI	Before or during study	CVD, AF, VTE, VHD, IHD, other	10 020	77.0 (6.9)	50	0.6	182	124	3 307

Appendix 2 to Oake N, Jennings A, Forster A, et al. Anticoagulation intensity and outcomes among patients prescribed oral anticoagulant therapy: a systematic review and meta-analysis. *CMAJ* 2008: 179(3):235-44.

Appendix 2: Detailed characteristics of 19 studies included in our systematic review and meta-analysis of anticoagulation intensity and risk of hemorrhagic and thromboembolic events* (part 2 of 2)

Study	Design	Setting	Drug	Method	Start of OAC use	Indication	N	Age, mean (SD or range)	Female (%)	Mean follow-up (yr)	No. of events		Person-years of observation
											Hemorrhagic events	Thrombo-embolic events	
Azar et al.[17]	RCT	C	PH, A	LI	Start of study	IHD	1 700	61.0 (11)	19	2.0	55	375	6 918
Hylek et al.[18]	RC	C	W	LI	Before study	AF	13 559	76.0 (54–94)	48	0.9	61	152	12 592
Oden et al.[19]	RC	ACC	NR	NR	Start of study	CVD, AF, VTE, VHD, IHD	42 451	70.5 (9.1)	42	1.4	243	NR	60 465
Overall							80 713	64.8	44	1.8	908	1 070	98 900

Note: A = acenocoumarol, ACC = anticoagulation clinic, AF = atrial fibrillation, APlA = antiphospholipid antibodies, C = community, CHF = chronic heart failure, CVD = cerebrovascular disease, E = Equidivision, EAFT = European Atrial Fibrillation Trial Study Group, ESPRIT = European and Australian Stroke Prevention in Reversible Ischaemia Trial, IHD = ischemic heart disease, LI = linear interpolation NR = not reported, OAC = oral anticoagulant, PC = prospective cohort, PH = phenprocoumon, PVD = peripheral vascular disease, RC = retrospective cohort, RCT = randomized controlled trial, SD = standard deviation, VHD = valvular heart disease, VTE = venous thromboembolism, W = warfarin.
*Atrial fibrillation patients with a previous ischemic stroke.
†Median.

References

1. Rosove MH, Brewer PM. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992;117:303-8.
2. Hutten BA, Prins MH, Gent M, et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 2000;18:3078-83.
3. Yasaka M, Minematsu K, Yamaguchi T. Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with non-valvular atrial fibrillation. Intern Med 2001;40:1183-8.
4. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. The European Atrial Fibrillation Trial Study Group. N Engl J Med 1995;333:5-10.
5. Chimowitz MI, Lynn MJ, Howlett-Smith H, et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 2005;352:1305-16.
6. Andersen PV, Aagaard J. Low-dose warfarin in patients with Carbomedics heart valve prostheses. Asian Cardiovasc Thorac Ann 2000;8:11-4.
7. Torn M, Algra A, Rosendaal FR. Oral anticoagulation for cerebral ischemia of arterial origin: high initial bleeding risk. Neurology 2001;57:1993-9.
8. Cheung CM, Tsoi TH, Huang CY. The lowest effective intensity of prophylactic anticoagulation for patients with atrial fibrillation. Cerebrovasc Dis 2005;20:114-9.
9. ESPRIT Study Group; Algra A. Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial. Lancet Neurol 2007;6:115-24.
10. Poli D, Antonucci E, Lombardi A, et al. Low rate of bleeding and thrombotic complications of oral anticoagulant therapy independent of age in the real-practice of an anticoagulation clinic. Blood Coagul Fibrinolysis 2003;14:269-75.
11. Tangelder MJD, Algra A, Lawson JA, et al. Optimal oral anticoagulant intensity to prevent secondary ischemic and hemorrhagic events in patients after infrainguinal bypass graft surgery. J Vasc Surg 2001;33:522-7.
12. Kearon C, Ginsberg JS, Kovacs MJ, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003;349:631-9.
13. Casais P, Luceros AS, Meschengieser S, et al. Bleeding risk factors in chronic oral anticoagulation with acenocoumarol. Am J Hematol 2000;63:192-6.
14. Palareti G, Manotti C, DAngelo A, et al. Thrombotic events during oral anticoagulant treatment: results of the inception-cohort, prospective, collaborative ISCOAT study: ISCOAT study group (Italian Study on Complications of Oral Anticoagulant Therapy). Thromb Haemost 1997;78:1438-43.
15. Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996;348:423-8.
16. Van Walraven C, Oake N, Wells PS, et al. Burden of potentially avoidable anticoagulant-associated hemorrhagic and thromboembolic events in the elderly. Chest 2007;131:1508-15.

Appendix 2 to Oake N, Jennings A, Forster A, et al. Anticoagulation intensity and outcomes among patients prescribed oral anticoagulant therapy: a systematic review and meta-analysis. *CMAJ* 2008: 179(3):235-44.

17. Azar AJ, Cannegieter SC, Deckers JW, et al. Optimal intensity of oral anticoagulant therapy after myocardial infarction. J Am Coll Cardiol 1996;27:1349-55.
18. Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003;349:1019-26.
19. Oden A, Fahlen M. Oral anticoagulation and risk of death: a medical record linkage study. BMJ 2002;325:1073-5.

Appendix 2 to Oake N, Jennings A, Forster A, et al. Anticoagulation intensity and outcomes among patients prescribed oral anticoagulant therapy: a systematic review and meta-analysis. *CMAJ* 2008: 179(3):235-44.